Abdulrahman Katib: Factor XI Inhibitors as the Next Frontier in the Thrombosis Treatment Landscape
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
“Factor XI inhibitors are quickly becoming one of the most intensely studied drug classes in thrombosis medicine today.
What makes them so exciting is the possibility of achieving meaningful antithrombotic protection while preserving hemostasis — something we have been striving for in anticoagulation for decades.
That said, true clinical efficacy still needs to be firmly established in some of our highest-risk populations, particularly cancer-associated thrombosis (CAT), where thrombosis biology and bleeding risk coexist in a very delicate balance.
On a personal level, I was truly privileged to be part of the MAGNOLIA and ASTER trials.
Being involved in research at this stage — before results are known — is a unique experience. It reminds you that every future guideline, every future practice change, starts with patients, investigators, and teams working together to answer difficult clinical questions.
I am genuinely looking forward to seeing the final publications and understanding where Factor XI inhibition will ultimately position itself in our thrombosis treatment landscape.”
More posts about Abdulrahman Katib.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda